Wegovy vs Saxenda: Head-to-Head for Women Across Every Life Stage

What Are Wegovy and Saxenda, and How Do They Work in Women?

Both Wegovy and Saxenda are injectable GLP-1 receptor agonists approved specifically for chronic weight management, not just blood sugar control. They slow gastric emptying, reduce appetite signaling in the hypothalamus, and increase satiety. The difference is the molecule: Wegovy contains semaglutide, Saxenda contains liraglutide.

In women, this matters for reasons that go beyond the label. GLP-1 receptors are expressed in the ovaries, endometrium, and the hypothalamic-pituitary axis, meaning these drugs interact with reproductive physiology in ways that are only beginning to be studied. Estrogen also modulates GLP-1 secretion, which is one reason why hormonal status across the female lifespan can shift how well either drug works for you.

The Core Pharmacology Difference

Semaglutide has a half-life of approximately 7 days, which is why one weekly injection sustains therapeutic drug levels. Liraglutide has a half-life of roughly 13 hours, requiring daily injections to maintain exposure. That difference in half-life also means that if you miss a dose of Saxenda, your drug level drops faster and more noticeably than with Wegovy.

GLP-1 and the Female Hypothalamus

Animal and early human data suggest GLP-1 receptor agonism modulates gonadotropin-releasing hormone (GnRH) pulsatility. This may explain reports of menstrual cycle changes on both drugs. Cycle irregularity reported by some women on GLP-1 therapy is likely multi-factorial: the direct hormonal effect, rapid weight loss itself causing cycle changes, and improved insulin sensitivity altering androgen levels in women with PCOS. These mechanisms are not yet fully disentangled in clinical trials, and this is an area where women have been underrepresented in the research.

Weight Loss Efficacy: What the Numbers Actually Show

Wegovy produces significantly greater weight loss than Saxenda. This is not a close comparison.

The STEP 1 trial randomized 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related condition) to semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean weight reduction was 15.3% of body weight in the semaglutide group versus 2.6% with placebo. Approximately 86% of participants were women, making this one of the more female-representative obesity trials published.

The SCALE Obesity and Prediabetes trial studied liraglutide 3 mg in 3,731 adults over 56 weeks and found a mean weight loss of 8.4 kg (roughly 8% of body weight) versus 2.8 kg with placebo. Again, the majority of participants were women.

Putting the Numbers in Body Terms

For a 200-pound woman, STEP 1 results suggest an average loss of about 30 pounds on Wegovy. The SCALE results suggest roughly 17 pounds on Saxenda. Both are meaningful. The gap is real.

Responder vs Non-Responder Rates

At 16 weeks, if you have not lost at least 5% of your body weight on Saxenda, SCALE data supports reconsidering the treatment. The FDA label for Wegovy uses the same 5% threshold at 16 weeks as a guide for reassessing continuation. Knowing your 16-week response gives you and your clinician a clear decision point.

Does Sex Affect Efficacy?

Trial-level sex-stratified data from STEP 1 were not published as a primary endpoint, so direct head-to-head by sex is not yet available. In the SCALE program, women and men lost similar percentages, though absolute kilogram losses differed due to starting weight differences. This is an acknowledged evidence gap: we do not yet have adequately powered sex-stratified subgroup analyses for either drug.

Dosing, Administration, and Titration for Women

Getting the titration right matters more than most prescribers discuss, because nausea is the number one reason women stop both drugs early.

Wegovy Titration Schedule

Wegovy starts at 0.25 mg weekly for 4 weeks, then increases by 0.25 mg every 4 weeks until reaching the maintenance dose of 2.4 mg weekly at week 17. The full titration takes approximately 16 to 20 weeks. Slower titration is not in the label but is widely used clinically when nausea is limiting.

Saxenda Titration Schedule

Saxenda starts at 0.6 mg daily for one week, increases by 0.6 mg each week, and reaches the 3 mg maintenance dose at week 5. This faster ramp can mean more concentrated nausea in the first 5 weeks compared to Wegovy's longer, slower climb.

Cycle-Phase Nausea Variation

Some women report that GLP-1 side effects, particularly nausea and appetite suppression, vary with their menstrual cycle. Progesterone slows gastric motility, so the luteal phase (the two weeks before your period) may amplify GLP-1-related nausea. This is not documented in label data, but it is a consistent clinical observation. Tracking your injection day relative to cycle day may help you identify a pattern.

Head-to-Head in Special Female Populations

No single published RCT has directly compared semaglutide 2.4 mg to liraglutide 3 mg head-to-head in a female-only or female-majority cohort of a specific reproductive subgroup. The framework below synthesizes available subgroup data, condition-specific trials, and published clinical guidance. Indirect comparisons carry inherent limitations, and readers should weight this information accordingly.

PCOS

Polycystic ovary syndrome affects an estimated 8 to 13% of reproductive-age women globally. Insulin resistance and hyperandrogenism are central features, and GLP-1 agonists address both indirectly through weight reduction and improved insulin sensitivity.

Liraglutide has a longer published record in PCOS. A 2019 randomized trial found liraglutide 1.8 mg (the diabetes dose, not the obesity dose) improved menstrual regularity, reduced androgen levels, and reduced weight versus placebo in women with PCOS and overweight. Semaglutide data in PCOS are accumulating faster now, and a 2023 real-world analysis found greater reductions in testosterone and SHBG normalization with semaglutide than historical liraglutide cohorts, though this was not a randomized comparison.

For women with PCOS trying to conceive, both drugs require stopping well before conception attempts. See the pregnancy section below.

Perimenopause and Menopause

Estrogen decline during perimenopause shifts fat distribution toward visceral adiposity and blunts the satiety response. GLP-1 agonists work against this backdrop, but the hormonal context matters.

Women in perimenopause or early post-menopause who are also using menopausal hormone therapy (MHT) may experience different weight trajectories than those not on MHT. There is currently no published RCT examining semaglutide or liraglutide specifically in perimenopausal women on concurrent MHT. The Menopause Society notes that weight gain in the menopausal transition is driven by hormonal change and aging simultaneously, meaning a GLP-1 alone may underperform expectations if the hormonal component is not addressed.

Clinically, some prescribers observe that perimenopausal women reach a weight-loss plateau earlier than younger premenopausal women on the same dose. Whether this is estrogen-mediated, age-mediated, or a combination is not yet established.

Postpartum

Neither drug is approved for postpartum use while breastfeeding. Animal studies show liraglutide transfers to breast milk; human lactation data for both drugs are absent. Women who used either drug before pregnancy and wish to resume postpartum should wait until breastfeeding is complete.

For postpartum weight retention specifically, lifestyle intervention remains the evidence-backed first line. GLP-1 therapy is an option after weaning, but the timing should be discussed with your clinician.

Thyroid Disease History

Both Wegovy and Saxenda carry a boxed warning for thyroid C-cell tumors based on rodent data. Neither drug is recommended for women with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Women with Hashimoto's thyroiditis or treated hypothyroidism are not excluded, but thyroid function monitoring is reasonable given that weight loss itself can alter levothyroxine requirements.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

Both Wegovy and Saxenda are contraindicated in pregnancy. This is a hard stop.

Animal studies with semaglutide showed fetal harm including skeletal malformations at clinically relevant exposures. Animal studies with liraglutide showed similar embryofetal toxicity. There are no adequate human data on either drug during pregnancy.

The FDA pregnancy category system has been replaced, but both drugs fall into a profile equivalent to the former category X for practical purposes: the risk to the fetus outweighs any potential benefit, and the drugs must be stopped.

How Far in Advance Do You Need to Stop?

Given semaglutide's 7-day half-life, it takes approximately 5 to 7 half-lives (5 to 7 weeks) to clear the drug substantially. The FDA label recommends stopping Wegovy at least 2 months before a planned pregnancy. Some clinicians extend this to 3 months for additional margin. Saxenda, with its shorter half-life, clears faster, but the same 2-month minimum applies given the embryonic sensitivity window.

GLP-1 and Fertility: A Double-Edged Consideration

Weight loss on GLP-1 therapy can restore ovulation in women with anovulatory PCOS, sometimes before the woman realizes her fertility has returned. This is documented: women on GLP-1 therapy for weight loss have become pregnant unexpectedly because they attributed their prior infertility to PCOS and did not use contraception. Use reliable contraception if you are on either drug and not actively trying to conceive.

Oral contraceptive pills may have altered absorption kinetics due to delayed gastric emptying on both drugs. For women relying on oral contraceptives, a barrier method as backup or switching to a non-oral method (IUD, implant, injection) is a reasonable precaution, particularly during dose escalation when gastric emptying effects are most pronounced.

Lactation

Human lactation transfer data for semaglutide and liraglutide are not available. Animal studies show liraglutide is present in rat milk. Based on the absence of safety data and the molecular weight and protein-binding characteristics of both drugs, neither is recommended during breastfeeding. Discontinue before or postpone resumption until breastfeeding is complete.

Side Effects: Where the Drugs Differ for Women

GLP-1 receptor agonist side effects are dominated by gastrointestinal complaints. The frequency and intensity differ between the two drugs.

Nausea and Vomiting

Nausea is the most common adverse event on both agents. In STEP 1, 44% of semaglutide participants reported nausea, mostly mild to moderate and concentrated in the titration phase. In the SCALE trial, nausea occurred in approximately 39.3% of liraglutide participants. The absolute difference is modest, but Saxenda's faster titration schedule compresses nausea into a shorter, more intense window for many women.

Injection Site Reactions

Both are subcutaneous injections. Saxenda's daily frequency means more total injections and more opportunities for site reactions. Rotating injection sites (abdomen, thigh, upper arm) is essential on Saxenda. Wegovy's weekly schedule gives skin more recovery time.

Gallbladder Events

Rapid weight loss on any agent increases gallstone risk. In STEP 1, gallbladder-related adverse events occurred in 2.6% of the semaglutide group versus 1.2% with placebo. Women already have a higher baseline risk of gallstones than men (female sex, obesity, pregnancy history, and estrogen use are all risk factors). This is a side effect category where being female matters, and it deserves a direct conversation with your clinician before starting either drug.

Hair Loss (Telogen Effluvium)

Diffuse hair shedding from rapid weight loss is documented with GLP-1 therapy. It is not a drug-specific effect but a consequence of caloric deficit and nutritional stress. Because female pattern hair loss and telogen effluvium from hormonal shifts (postpartum, perimenopause) are already common, women on GLP-1 therapy are at compounded risk. Adequate protein intake (at minimum 1.2 g/kg ideal body weight) and micronutrient monitoring (ferritin, zinc, B12) reduce but do not eliminate this risk.

Who Is Right for Wegovy vs Saxenda: A Life-Stage Guide

Choosing between these two drugs is not purely about efficacy. Access, adherence, and individual medical history all factor in.

Wegovy Is Likely the Better Fit If:

• You want maximum weight loss efficacy and access is reliable
• You prefer weekly over daily injections
• You have PCOS and are not planning pregnancy in the near term
• You are post-menopause and want the strongest pharmacological support for visceral fat reduction
• Your clinician is titrating you slowly to manage nausea, and a longer titration window fits that plan

Saxenda May Be the Better Fit If:

• Wegovy is on backorder or your insurance covers Saxenda but not Wegovy
• You have had a severe reaction to semaglutide and want a different GLP-1 molecule
• You prefer daily feedback on dosing (some women find daily injections feel more controllable)
• You need flexibility to hold or reduce a dose quickly (shorter half-life means faster drug clearance if you develop a problem)
• You are transitioning back from pregnancy and your clinician wants to restart a GLP-1 with faster titration adjustment capability

Neither Drug Is Appropriate If:

• You are pregnant or actively trying to conceive without confirmed ovulatory status
• You are currently breastfeeding
• You have a personal or family history of MTC or MEN 2
• You have a history of pancreatitis (both drugs carry a pancreatitis warning; the causal link is not fully established but the label carries the warning)

Switching from Wegovy to Saxenda (or the Other Way)

Switching Wegovy to Saxenda is a step down in expected efficacy, and it is worth being clear about that before you switch.

Saxenda to Wegovy

This is the more common and more evidence-aligned direction. Women who reach a weight loss plateau on Saxenda or who cannot tolerate the daily injection burden are reasonable candidates to switch to Wegovy. A washout period is generally not required given both drugs work at the same receptor. Most clinicians start Wegovy at the 0.25 mg weekly initiation dose after stopping Saxenda the previous day, then titrate normally.

Wegovy to Saxenda

Reasons women switch down include Wegovy supply shortage, cost without insurance coverage, or a new contraindication developing (such as a planned pregnancy requiring drug clearance). When switching from Wegovy to Saxenda, expect that your weight loss may slow or plateau, and that you will need to re-titrate Saxenda from the lowest dose given the different receptor kinetics and potential GI sensitivity reset.

The Semaglutide Supply Issue

The GLP-1 supply chain has been intermittent since 2022. If Wegovy is unavailable, some prescribers have bridged patients with Ozempic (semaglutide 1 mg, the diabetes formulation) or switched to Saxenda. Bridging with compounded semaglutide carries its own set of quality and regulatory concerns outside the scope of this article. A supply interruption is a clinical situation worth planning for in advance with your prescribing clinician.

Dr. Elena Vasquez, MD, WomanRx clinical reviewer and obesity medicine specialist, notes: "For my perimenopausal patients especially, I find that the conversation about which GLP-1 to use cannot be separated from the conversation about estrogen status. A woman losing muscle mass from estrogen decline and caloric restriction on a GLP-1 needs resistance training and possibly concurrent hormone evaluation, not just a drug comparison chart."

Monitoring and Follow-Up Specific to Women

Both drugs require follow-up beyond a prescription refill. The following labs and assessments are relevant specifically for female patients.

• Thyroid function (TSH) at baseline and if symptoms change, given the boxed warning and the common co-occurrence of thyroid disease in women
• Ferritin, B12, and zinc at 3 to 6 months if significant weight loss is occurring and hair shedding appears
• Fasting glucose and HbA1c at baseline and annually, with attention to women with PCOS who have elevated diabetes risk
• Bone mineral density discussion for perimenopausal and post-menopausal women, since rapid weight loss may accelerate bone loss
• Menstrual cycle tracking as informal monitoring of reproductive hormone recovery in women with PCOS
• Pregnancy test if periods are irregular and sexual activity is occurring, given the ovulation-restoration effect described above

For women on oral contraceptives, a follow-up conversation about contraceptive method adequacy within the first 3 months of GLP-1 therapy is appropriate given the gastric emptying effect on oral drug absorption.